NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview at the Emerging Growth Conference on Thursday, July 18, 2024 at 10:50 am ET.
馬薩諸塞州劍橋，2024年7月11日 /PRNewswire/ — 專注於改變心臟代謝疾病的臨床階段生物技術公司NeuroBo Pharmicals, Inc.（納斯達克股票代碼：NRBO）今天宣佈，總裁兼首席執行官金亨憲和首席財務官馬歇爾·伍德沃斯將在美國東部時間2024年7月18日星期四上午10點50分的新興增長會議上介紹公司概況。
During the virtual presentation, management will provide an update on the clinical development of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
在虛擬演示中，管理層將介紹 DA-1726 的最新臨床開發情況，這是一種用於治療肥胖的新型雙氧調節素（OXM）類似物激動劑，可作爲胰高血糖素樣肽1受體（GLP1R）和胰高血糖素受體（GCGR）。
After the presentation, NeuroBo management will open the floor for questions. Please submit your questions in advance to [email protected], or ask your questions during the event.
演講結束後，NeuroBO管理層將開放提問。請提前將您的問題提交到 [email protected]，或在活動期間提問。
Please register using this link to attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at [email protected].
請使用此鏈接註冊參加虛擬會議並接收已發佈的任何更新。要安排在會議之外與管理層會面，請通過 [email protected] 與邁克爾·米勒聯繫。
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
關於 NeuroBo 製藥
NeuroBo Pharmaceuticals, Inc. 是一家臨床階段的生物技術公司，專注於改變心臟代謝疾病。該公司目前正在開發用於治療肥胖症的 DA-1726，並正在開發用於治療代謝功能障礙相關性脂肪肝炎 (MASH) 的 DA-1241。DA-1726 是一種新型的氧調節素 (OXM) 類似物，可用作胰高血糖素樣肽 1 受體 (GLP1R) 和胰高血糖素受體 (GCGR) 雙重激動劑。OxM 是一種天然存在的腸道激素，可激活 GLP1R 和 GCGR，從而減少食物攝入量，同時增加能量消耗，因此與選擇性的 GLP1R 激動劑相比，有可能顯著減輕體重。DA-1241 是一種新型 G 蛋白偶聯受體 119 (GPR119) 激動劑，可促進關鍵腸道肽 GLP-1、GIP 和 PYY 的釋放。在臨床前研究中，DA-1241 顯示出對肝臟炎症、脂質代謝、體重減輕和葡萄糖代謝具有積極作用，可減少肝臟脂肪變性、肝炎和肝纖維化，同時還改善了血糖控制。
For more information, please visit .
欲了解更多信息，請訪問。
Contacts:
聯繫人：
NeuroBo Pharmaceuticals
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
[email protected]
紐羅博製藥
馬歇爾·H·伍德沃思
首席財務官
+1-857-299-1033
[電子郵件保護]
Rx Communications Group
Michael Miller
+1-917-633-6086
[email protected]
Rx 通信組
邁克爾·米勒
+1-917-633-6086
[電子郵件保護]
SOURCE NeuroBo Pharmaceuticals, Inc.
來源 NeuroBo 製藥公司